Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $151.31 USD
Change Today +7.01 / 4.86%
Volume 697.1K
ANAC On Other Exchanges
Symbol
Exchange
Berlin
As of 8:10 PM 07/28/15 All times are local (Market data is delayed by at least 15 minutes).

anacor pharmaceuticals inc (ANAC) Snapshot

Open
$145.55
Previous Close
$144.30
Day High
$153.30
Day Low
$142.97
52 Week High
07/21/15 - $156.93
52 Week Low
07/29/14 - $16.13
Market Cap
6.6B
Average Volume 10 Days
913.6K
EPS TTM
$-1.83
Shares Outstanding
43.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ANACOR PHARMACEUTICALS INC (ANAC)

anacor pharmaceuticals inc (ANAC) Related Bloomberg News

View More Bloomberg News

anacor pharmaceuticals inc (ANAC) Related Businessweek News

No Related Businessweek News Found

anacor pharmaceuticals inc (ANAC) Details

Anacor Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. It markets KERYDIN (tavaborole) topical solution for the treatment of onychomycosis of the toenails. The company’s lead product candidate includes AN2728, anti-inflammatory product, which is in Phase III clinical trials for the treatment of mild-to-moderate atopic dermatitis and psoriasis. It is also developing AN2898, an anti-inflammatory product candidate, which has completed Phase IIa clinical trials for the treatment of atopic dermatitis and psoriasis; AN3365, an antibiotic product candidate for the treatment of infections caused by Gram-negative bacteria; and AN2718, an antifungal product candidate, which is in Phase I clinical trials for the treatment of onychomycosis and fungal infections of the skin. The company has research collaborations with Drugs for Neglected Diseases initiative to develop new therapeutics for human African trypanosomiasis, visceral leishmaniasis, and Chagas disease; research and development collaboration with GlaxoSmithKline LLC for tuberculosis (TB); research, license, and commercialization agreement with Eli Lilly and Company for an animal health indication; and research agreement with The Bill & Melinda Gates Foundation for filarial worm diseases, TB, and cryptosporidiosis. The company was formerly known as AnaMax, Inc. and changed its name to Anacor Pharmaceuticals, Inc. in October 2002. Anacor Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Palo Alto, California.

100 Employees
Last Reported Date: 03/16/15
Founded in 2000

anacor pharmaceuticals inc (ANAC) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $457.0K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $365.0K
Chief Commercial Officer and Executive Vice P...
Total Annual Compensation: $335.0K
Senior Vice President of Drug Development
Total Annual Compensation: $272.5K
General Counsel, Senior Vice President and Se...
Total Annual Compensation: $257.7K
Compensation as of Fiscal Year 2014.

anacor pharmaceuticals inc (ANAC) Key Developments

Anacor Pharmaceuticals, Inc. Announces Preliminary Top-Line Results from its Two Phase 3 Pivotal Studies of Crisaborole Topical Ointment

Anacor Pharmaceuticals, Inc. announced preliminary top-line results from its two Phase 3 pivotal studies of Crisaborole Topical Ointment, 2% (formerly AN2728), a novel non-steroidal topical anti-inflammatory phosphodiesterase-4 (PDE-4) inhibitor in development for the potential treatment of mild-to-moderate atopic dermatitis in children and adults. In both studies, crisaborole achieved statistically significant results on all primary and secondary endpoints and demonstrated a safety profile consistent with previous studies. Atopic dermatitis is a chronic rash characterized by inflammation and itching. Lesions of atopic dermatitis are commonly red, elevated and oozing patches and are often accompanied by pruritus (itching). The lesions' lichenification, a thickening of the skin with exaggerated skin lines, is considered to be a hypertrophic response to chronic rubbing. Based on available sources, the company believe approximately 18 to 25 million people in the United States suffer from atopic dermatitis, and 80% to 90% have mild or moderate disease. Atopic dermatitis can persist into adulthood, but most commonly appears in childhood, with estimates that between 8% and 18% of all infants and children in the United States are affected by the disease.

Anacor Pharmaceuticals, Inc. - Special Call

To discuss the top-line results from its Phase 3 pivotal studies of Crisaborole Topical Ointment, 2% (formerly AN2728) for the potential treatment of mild-to-moderate atopic dermatitis in children and adults

Anacor Pharmaceuticals Amends Distribution, Commercialization Deal with Sandoz Inc

Anacor Pharmaceuticals announced that it has amendment to its distribution and commercialization agreement with Sandoz Inc., a Novartis (NVS) company, under which PharmaDerm, the branded dermatology division of Sandoz, distributes and commercializes KERYDIN (tavaborole) topical solution, 5%, in the U.S. KERYDIN (tavaborole) is an antifungal topical solution used to treat a fungal infection of the toenail called onychomycosis.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ANAC:US $151.31 USD +7.01

ANAC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ANAC.
View Industry Companies
 

Industry Analysis

ANAC

Industry Average

Valuation ANAC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 197.1x
Price/Book 87.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 191.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ANACOR PHARMACEUTICALS INC, please visit www.anacor.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.